RxDoctor Payments Data

Chinyere Ihunnah, APRN

Acute Care · Dallas, TXNPI 1821683525

Payments from drug & device makers

$540in general payments, 2019–2025

Across 21 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$218
  • Novartis$46
  • Upsher-smith Laboratories LLC$43
  • Neurelis, Inc.$29
  • Bristol Myers Squibb$29
  • Lundbeck LLC$27
  • plus $148 from 9 others

What the payments were for

  • Speaking & faculty fees$20037%
  • Food & beverage$34063%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$540 in reported general payments places this provider in the 55th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$56,154
Medicare patients
84
Services billed
6,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate15$104,348
Emgality PenGalcanezumab-Gnlm98$88,225
Nurtec OdtRimegepant Sulfate44$81,717
UbrelvyUbrogepant31$56,984
Glatiramer Acetate23$45,523
Dalfampridine ErDalfampridine42$16,292
Sumatriptan Succinate66$2,516
Gabapentin112$2,395
Dimethyl Fumarate13$2,020
Baclofen67$1,570
Carbidopa-LevodopaCarbidopa/Levodopa37$1,512
RizatriptanRizatriptan Benzoate19$1,065
Propranolol Hcl ErPropranolol Hcl18$906
Topiramate70$884
Levetiracetam18$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$22$81,71744 claims
Upsher-smith Laboratories LLCTopiramate$43$88470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,323 acute care providers in Texas.

Other acute care in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →